Compare ARGX & DLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | DLTR |
|---|---|---|
| Founded | 2008 | 1986 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.6B | 20.8B |
| IPO Year | 2017 | 1995 |
| Metric | ARGX | DLTR |
|---|---|---|
| Price | $822.96 | $131.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 18 |
| Target Price | ★ $971.89 | $118.24 |
| AVG Volume (30 Days) | 306.9K | ★ 2.9M |
| Earning Date | 02-26-2026 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 23.27 | N/A |
| Revenue | $3,683,281,000.00 | ★ $18,960,900,000.00 |
| Revenue This Year | $91.44 | $13.27 |
| Revenue Next Year | $36.90 | $6.30 |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | 92.98 | ★ 156.37 |
| 52 Week Low | $510.06 | $61.80 |
| 52 Week High | $934.62 | $135.18 |
| Indicator | ARGX | DLTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 65.86 |
| Support Level | $787.02 | $122.70 |
| Resistance Level | $855.43 | $135.18 |
| Average True Range (ATR) | 17.10 | 3.93 |
| MACD | -4.72 | 0.03 |
| Stochastic Oscillator | 37.41 | 77.62 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Dollar Tree operates discount stores across the United States and Canada, with over 8,800 shops under its namesake banner. About 50% of Dollar Tree's sales in fiscal 2024 were consumables (including food, health and beauty, and cleaning products), around 45% variety items (including toys and homewares), and 5% seasonal items. Dollar Tree sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. The retailer has agreed to sell Family Dollar (with about 7,000 stores) to private equity investors for $1 billion.